Publicaciones Imprimir Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025 Jan; 82 (1):107-119 Epub 2024 July 10 View PubMed Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14 [Epub ahead of print] View PubMed Storandt MH, Zemla TJ, Patell K, Naleid N, Gile JJ, Tran NH, Chakrabarti S, Jin Z, Borad M, Mahipal A. Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study. Oncologist. 2024 Nov 4; 29 (11):986-996 View PubMed Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Jul; 26 (7):938-948 Epub 2024 Apr 23 View PubMed Qian X, Liu E, Zhang C, Feng R, Tran N, Zhai W, Wang F, Qin Z. Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor. J Gastrointest Oncol. 2024 Jun 30; 15 (3):1198-1213 Epub 2024 June 27 View PubMed Van Treeck BJ, Olave MC, Watkins RD, Lu H, Moreira RK, Mounajjed T, Johnson MJ, Smith CY, Ilyas SI, Tran NH, Jenkins SM, Reed KA, Smoot R, Mahipal A, Allende D, Graham RP. WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB (Oxford). 2024 Apr 24 [Epub ahead of print] View PubMed Imperial R, Mosalem O, Majeed U, Tran NH, Borad MJ, Babiker H. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Clin Exp Gastroenterol. 2024; 17:121-134 Epub 2024 Apr 18 View PubMed Emiloju OE, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A, Mitchell J, Thiels C, Mathis K, McWilliams R, Hubbard J, Sinicrope F, Shi Q, Jin Z. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precis Oncol. 2024 Jan; 8:e2300127 View PubMed Jorgenson LC, Torbenson MS, Halfdanarson TR, Kankeu Fonkoua LA, Tran NH, Roberts LR, Smoot RL, Goenka AH, Thompson SM. Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes. Front Nucl Med. 2024; 4:1480471 Epub 2024 Nov 27 View PubMed Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol 2024; 20 (30):2241-2248 Epub 2024 June 04 View PubMed Washburn L, Mahipal A, Jatoi A, Kottschade L, Tran N. Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review. J Gastrointest Oncol. 2023 Dec 31; 14 (6):2627-2636 Epub 2023 Dec 12 View PubMed Hassan H, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, Abdellatief A, Katta R, Tran N, Jin Z, Cleary S, Roberts L, Mahipal A. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. Eur J Surg Oncol. 2023 Nov; 49 (11):106994 Epub 2023 July 27 View PubMed Palmer ME, Gile JJ, Storandt MH, Jin Z, Zemla TJ, Tran NH, Mahipal A. Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study. Cancers (Basel). 2023 Oct 6; 15 (19) Epub 2023 Oct 06 View PubMed Leiting JL, Hernandez MC, Bergquist JR, Yonkus JA, Abdelrahman AM, Torbenson MS, Tran NH, Halfdanarson TR, Graham RP, Smoot RL, Truty MJ. Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular Carcinoma. In Vivo. 2023 Sep-Oct; 37 (5):1940-1950 View PubMed Tran NH, Almodallal Y, Batheja M, Martin NA, Le-Rademacher J, Ridgeway JL, Sia IG, Jatoi A. Social determinants of health: a need for better data capture in Asian American patients with hepatocellular cancer. Support Care Cancer. 2023 Aug 30; 31 (9):543 View PubMed Kumar-Sinha C, Vats P, Tran N, Robinson DR, Gunchick V, Wu YM, Cao X, Ning Y, Wang R, Rabban E, Bell J, Shankar S, Mannan R, Zhang Y, Zalupski MM, Chinnaiyan AM, Sahai V. Genomics driven precision oncology in advanced biliary tract cancer improves survival. Neoplasia. 2023 Aug; 42:100910 Epub 2023 May 31 View PubMed Elhariri A, Starr JS, Bagaria S, Tran N, Babiker H. A Unicorn Disease: The Large Duct Variant of Invasive Ductal Adenocarcinoma of the Pancreas. Cureus. 2023 Jul; 15 (7):e41430 Epub 2023 July 05 View PubMed Storandt MH, Tran N, Martin N, Jatoi A. Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Cancer Immunol Immunother. 2023 Jul; 72 (7):2515-2520 Epub 2023 Mar 06 View PubMed Marell PS, Wieland J, Babiker HM, Fonkoua LK, Borad MJ, Jatoi A, Tran NH. An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies Current Hepatology Reports. 2023; 22:1-13. Storandt MH, Tran NH, Ehret CJ, Hanna M, Jochum J, Moynagh MR, Jatoi A. Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival. World J Surg Oncol. 2023 Jun 8; 21 (1):177 Epub 2023 June 08 View PubMed Ahn JC, Tran NH, Yang JD. Systemic therapy in advanced hepatocellular carcinoma. Clin Mol Hepatol. 2023 Apr; 29 (2):516-519 Epub 2023 Feb 20 View PubMed Tran NH, Nguyen PL, Martin NA, Asiedu G, Le-Rademacher JG, Jatoi A. "It's Like You Stuck a Pin in It:" African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors. Am J Hosp Palliat Care. 2023 Mar; 40 (3):337-340 Epub 2022 Apr 20 View PubMed Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2022 Oct 22; 14 (21) View PubMed Tran NH, Munoz S, Thompson S, Hallemeier CL, Bruix J. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology. 2022 Oct; 76 (4):1203-1218 Epub 2022 July 30 View PubMed Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Target Oncol. 2022 Sep; 17 (5):529-538 Epub 2022 Sept 02 View PubMed Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, Merrell KW, Thiels CA, Hallemeier CL, Warner SG, Haddock MG, Grotz TE, Tran NH, Smoot RL, Ma WW, Cleary SP, McWilliams RR, Nagorney DM, Halfdanarson TR, Kendrick ML, Truty MJ. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2022 Sep; 20 (9):1023-1032.e3 View PubMed Liddell SS, Chakrabarti S, Wintheiser GA, Zemla TJ, Shi Q, Tella SH, Jin Z, Wookey VB, Hassan H, Tran NH, Borad MJ, Mahipal A. Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precis Oncol. 2022 Jun; 6:e2200003. View PubMed Thompson SM, Suman G, Torbenson MS, Chen ZE, Jondal DE, Patra A, Ehman EC, Andrews JC, Fleming CJ, Welch BT, Kurup AN, Roberts LR, Watt KD, Truty MJ, Cleary SP, Smoot RL, Heimbach JK, Tran NH, Mahipal A, Yin J, Zemla T, Wang C, Fogarty Z, Jacobson M, Kemp BJ, Venkatesh SK, Johnson GB, Woodrum DA, Goenka AH. PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68) Ga-PSMA-11 PET Using Cyclotron-Produced (68) Ga. Hepatol Commun. 2022 May; 6 (5):1172-1185 Epub 2021 Nov 15 View PubMed Gile J, Jatoi A, Wee Ma W, Borad M, Tran NH. Reply to A. Rizzo et al. JCO Precis Oncol 2022 Mar; 6:e2200061 View PubMed Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. 2022 Feb; 24 (2):187-193 Epub 2022 Jan 21 View PubMed Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31 View PubMed Torbenson M, McCabe CE, O'Brien DR, Yin J, Bainter T, Tran NH, Yasir S, Chen ZE, Dhanasekaran R, Ahn KS, Roberts LR, Wang C. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification. Hum Pathol. 2022 Jan; 119:15-27 Epub 2021 Sept 27 View PubMed Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol. 2022 Jan; 6:e2100156 View PubMed Tran NH, Bekaii-Saab T. Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. JAMA Netw Open 2021 Nov 1; 4 (11):e2134458 Epub 2021 Nov 01 View PubMed Li JJ, Zhu M, Kashyap PC, Chia N, Tran NH, McWilliams RR, Bekaii-Saab TS, Ma WW. The role of microbiome in pancreatic cancer. Cancer Metastasis Rev. 2021 Sep; 40 (3):777-789 Epub 2021 Aug 28 View PubMed Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep. 2021 Aug; 3 (4):100304 Epub 2021 May 10 View PubMed Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs. 2021 Aug; 39 (4):1072-1080 Epub 2021 Mar 01 View PubMed Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28 View PubMed Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2020 Jan 1; 106 (1):124-133 Epub 2019 Sept 05 View PubMed Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase II trial of neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2019. Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 2015 Oct 5; 4 (10):e169 Epub 2015 Oct 05 View PubMed Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015 Sep; 7 (5):252-262 Epub 2015 July 05 View PubMed Tran N, Stapleton J, Zhang Y, Harlow S, Yang H, Moyer CA. Contraceptive practices of women visiting a gynecology clinic in Beijing, China. Int J Gynaecol Obstet. 2011 Jan; 112 (1):64-5 Epub 2010 Oct 18 View PubMed PST-20467935 Inicio Publicaciones